Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Hellsten, Rebecka ^a   Johansson, Martin ^a   Dahlman, Anna ^a   Sterner, Olov ^a   Bjartell, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; GALIELLALACTONE; HERMES ANTIGEN; INTERLEUKIN 6; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; LACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; CANCER STEM CELL; CYTOLOGY; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960129491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022118     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Sengupta A, Cancelas JA, (2010) Cancer stem cells: a stride towards cancer cure? J Cell Physiol 225: 7-14.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
4. Lang SH, Frame FM, Collins AT, (2009) Prostate cancer stem cells. J Pathol 217: 299-306.
5. Kelly K, Yin JJ, (2008) Prostate cancer and metastasis initiating stem cells. Cell Res 18: 528-537.
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
7. Maitland NJ, Collins AT, (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
8. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
9. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, et al. (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19: 327-337.
10. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338.
11. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, et al. (2010) Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32: 1195-1201.
12. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
13. Li T, Su Y, Mei Y, Leng Q, Leng B, et al. (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 90: 234-244.
14. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, et al. (2010) High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer Res 70: 5163-5173.
15. Bromberg J, (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142.
16. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, et al. (2008) Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728.
17. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, et al. (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97: 378-383.
18. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, et al. (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9: R83.
19. Costantino L, Barlocco D, (2008) STAT 3 as a target for cancer drug discovery. Curr Med Chem 15: 834-843.
20. Deng J, Grande F, Neamati N, (2007) Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 7: 91-107.
21. Jing N, Tweardy DJ, (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16: 601-607.
22. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, et al. (2008) Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 68: 269-280.
23. Johansson M, Sterner O, (2002) Synthesis of (-)-galiellalactone. J Antibiot (Tokyo) 55: 663-665.
24. Weidler M, Rether J, Anke T, Erkel G, (2000) Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett 484: 1-6.
25. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, et al. (2001) Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7: 2941-2948.
26. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
27. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, et al. (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70: 5163-5173.
28. Lindgren D, Bostrom AK, Nilsson K, Hansson J, Sjolund J, et al. (2011) Isolation and characterization of progenitor-like cells from human renal proximal tubules. Am J Pathol 178: 828-837.
29. Zhang K, Waxman DJ, (2010) PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer 9: 319.
30. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P, (2010) Targeting of integrin beta1 and kinesin 2alpha by microRNA 183. J Biol Chem 285: 5461-5471.
31. Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A, (2009) Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol 3: 128-138.
32. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15: 4234-4241.
33. Saini V, Shoemaker RH, (2010) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101: 16-21.
34. Wei C, Guomin W, Yujun L, Ruizhe Q, (2007) Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 6: 763-768.
35. Pfeiffer MJ, Schalken JA, (2010) Stem cell characteristics in prostate cancer cell lines. Eur Urol 57: 246-254.
36. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI, (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2: 162.
37. Maitland NJ, Collins AT, (2008) Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 105: 931-939.
38. Villalva C, Martin-Lanneree S, Cortes U, Dkhissi F, Wager M, et al. (2010) STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: A potential for targeted therapy? Int J Cancer 128: 826-838.
39. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104: 16158-16163.
40. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, et al. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 69: 827-837.
41. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, et al. (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122: 777-785.